Welcome to our dedicated page for OMADA HEALTH news (Ticker: OMDA), a resource for investors and traders seeking the latest updates and insights on OMADA HEALTH stock.
Omada Health, Inc. (Nasdaq: OMDA) is a virtual-first, between-visit healthcare provider focused on cardiometabolic conditions such as diabetes, hypertension, prediabetes, and obesity, as well as musculoskeletal issues. The OMDA news page on Stock Titan aggregates company announcements, clinical updates, product news, and financial disclosures so readers can follow how Omada’s virtual care platform and GLP-1 programs evolve over time.
News about Omada Health frequently covers quarterly and annual financial results, including revenue trends, member growth, and updates shared through earnings press releases and related Form 8-K filings. Investors can also see announcements about Omada’s participation in major healthcare and investor conferences, where senior management presents the company’s strategy and performance.
Because Omada operates in digital chronic care and GLP-1 support, its news flow also includes clinical and real-world evidence analyses from Omada’s GLP-1 Care Tracks and Enhanced GLP-1 Care Track, along with updates from the Omada Insights Lab ANSWERS Initiative. These releases describe findings on medication persistence, weight outcomes, and weight maintenance after GLP-1 discontinuation for members enrolled in Omada programs.
Product and platform updates are another recurring theme, such as the launch of Meal Map, an AI-powered nutrition experience focused on nutrient quality, and announcements about OmadaSpark, the company’s AI-powered nutrition education tool. Omada also issues news about its prescribing and medication management capability for anti-obesity medications, including GLP-1s, and about enhancements to its AI-enabled support tools.
By reviewing the OMDA news feed, readers can track how Omada’s member base, customer relationships, GLP-1-related offerings, and AI-powered capabilities are described in official communications, and how the company positions its role in chronic care and virtual healthcare delivery.
Omada Health (Nasdaq: OMDA) expanded its virtual care platform on Feb 19, 2026 to add Omada for Cholesterol, integrating cholesterol management with weight, glucose, blood pressure, and GLP-1 support.
The program uses human-led coaching amplified by AI, multidisciplinary teams, and medication adherence guidance to support day-to-day behavior change. According to Omada, up to 70% of adults with obesity have high cholesterol and only 41% of U.S. adults with atherosclerotic cardiovascular disease reached LDL-C <70 mg/dL.
Omada Health (Nasdaq: OMDA) will release its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026 after market close and host a conference call the same day at 4:30 pm ET. A live audio webcast and replay will be available at the company's investor site for about 12 months.
Omada Health (Nasdaq: OMDA) reported preliminary, unaudited revenue for Q4 2025 of $72M–$74M (up ~50%–54% YoY) and full-year 2025 revenue of $256M–$258M (up ~51%–52% YoY). Total members reached approximately 886,000 as of December 31, 2025, a 55% increase year-over-year. Results are preliminary and subject to completion of year-end closing procedures and the annual independent audit. Omada plans to release audited Q4 and FY2025 results on March 5, 2026 and will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Omada Health (Nasdaq: OMDA) released a 12-month real-world analysis of 965 members in its Enhanced GLP-1 Care Track showing durable weight loss when behavioral support is paired with GLP-1 medications. Members who persisted on medication for 12 months averaged 18.4% weight loss, versus 11.9% in cited real-world evidence; overall program members averaged 16.3% weight loss. Persistence at one year was 67%, higher than the 47–49% comparator. The analysis used pharmacy claims and clinical data and highlights Omada’s prescription and medication-management capability for anti-obesity medications.
Omada Health (NASDAQ: OMDA) announced senior management will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The company will present on Wednesday, Jan. 14, 2026 at 9:00 a.m. PST. A live webcast and subsequent replay will be available at https://investors.omadahealth.com/news-events/events.
Omada Health (Nasdaq: OMDA) announced that senior management will participate in the 8th Annual Evercore Healthcare Conference in Miami.
The company will host a fireside chat on Wednesday, December 3, 2025 at 1:20 pm ET. A live webcast and a replay will be available at https://investors.omadahealth.com/news-events/events.
Omada Health (NASDAQ: OMDA) reported Q3 2025 results: revenue $68.0M (+49% year-over-year) and total members 831,000 (+53% YoY). Gross margin improved to 66% and non-GAAP gross margin to 68%. Omada posted a net loss of $3M versus $9M a year earlier and delivered its first quarter of positive adjusted EBITDA: $2M. Cash and cash equivalents were $199M at September 30, 2025. Management announced a new GLP-1 prescribing offering, launched AI nutrition product Meal Map, and published its 30th peer-reviewed manuscript with weight-maintenance data after GLP-1 discontinuation. Full-year 2025 guidance was raised to $251.5M–$254.5M revenue and adjusted EBITDA of a $2M loss to breakeven.
Omada Health (NASDAQ: OMDA) announced a planned nationwide prescribing capability for anti-obesity medications (AOM), including GLP-1s, to integrate medication management into its evidence-based behavior change weight program.
The company reported 53% year-over-year member growth through Q3 2025 and said the prescribing option will be available in all 50 states. Omada cited published analyses showing a 28% greater weight loss at 4 months in its Enhanced GLP-1 Care Track and 0.8% average weight change 12 months after discontinuation in one analysis versus 11–12% gain in trials.
Omada Health (Nasdaq: OMDA) will present two ObesityWeek 2025 posters (Nov 4-5, 2025) reporting real-world evidence that Omada’s behavior-change program may improve outcomes for members on or previously on GLP-1 medications for weight loss.
Key findings: 84% persistence at 24 weeks (n=1,124) with greater weight loss for persistent users (12.1% vs 7.4%), a 54% higher odds of persistence per 10 additional weekly engagements, and an average 0.8% weight change at 12 months post-discontinuation (n=95), with 63.2% maintaining or losing weight.
Omada Health (Nasdaq: OMDA) appointed Thomas Tsang, MD, MPH as Chief Medical Officer on October 27, 2025. Dr. Tsang will lead clinical quality, outcomes, strategy, and innovation across Omada’s multi-condition virtual care platform.
He brings prior roles including founding CEO of Valera Health (raised >$75 million; scaled to >500 employees), CMO at Merck Healthcare Services and Solutions, and policy roles at the Office of the National Coordinator and the U.S. House Ways and Means Committee. Omada highlights its GLP-1 Care Track serving over 100,000 members, recent AI launches OmadaSpark and Meal Map, and a customer base exceeding 2,000 organizations.